Potentially Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions
Interventions
Comprehensive Nutrition Group:Patients received daily oral supplementation with enteral nutrition formula (Nutricia, Netherlands
500 kcal/day) in addition to a regular diet from the initial hospitalization throughout neoadjuvant therapy. Intraoperative placement of a nasojejunal tube or jejunostomy was performed. Postoperativel
Neoadjuvant Nutrition Group:Patients followed identical inpatient protocols to the Comprehensive Nutrition Group from initial hospitalization until discharge. Following discharge criteria fulfillment,
Conventional Nutrition Group:Patients main
Sponsors
Jinling Hospital, Medical School of Nanjing University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary informed consent signed; able to objectively describe symptoms, no severe infections/respiratory insufficiency, and cooperative. 2. Age >=20 and <=80 years, regardless of gender. 3. Histopathologically confirmed esophageal carcinoma via endoscopic biopsy. 4. Clinical stage cT1b-2N+ or cT3-4aNanyM0, requiring preoperative neoadjuvant chemoradiotherapy (nCRT) as determined by multidisciplinary team (MDT) evaluation. 5. Initial nutritional assessment score <=3 on the Patient-Generated Subjective Global Assessment (PG-SGA) (no or mild malnutrition). 6. Absence of contraindications to nCRT or subsequent surgery. 7. Ability to adhere to prescribed medication regimens and follow-up schedules. 8. Non-pregnant and non-lactating females.
Exclusion criteria
Exclusion criteria: 1. Failure to meet inclusion criteria or deemed unsuitable for participation by principal investigator 2. Metabolic disorders (e.g., diabetes mellitus, thyroid dysfunction) or severe comorbidities affecting cardiac, hepatic, pulmonary, renal, or neurological systems 3. Weight loss =10% within 6 months, BMI <18.5 kg/m^2, Subjective Global Assessment (SGA) grade C, or serum albumin <30 g/L without hepatic/renal dysfunction 4. Major postoperative complications (e.g., significant hemorrhage, reoperation) 5. Participation in any investigational drug trials (including the study drug in this trial) within 3 months prior to enrollment 6. Allergic constitution/history of anaphylaxis to study drugs/anesthetics. 7. History of hypersensitivity to study drug components, structurally related compounds, or anesthetic agents; allergic predisposition 8. Incomplete study-related documentation during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PG-SGA;EORTC QLQ-C30; | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight ;Survival time; | — |
Countries
China
Contacts
Public ContactYi Shen
Jinling Hospital, Medical School of Nanjing University
Outcome results
None listed